Patients Find Weight Loss Drug Zepbound A Game Changer, But Makers See Production Delay Until 2025

The GLP-1 class of drugs for weight loss has gained tremendous popularity but is struggling with a shortage that could extend into 2025. Who says that? The companies that make those drugs predict. The weight loss drug frenzy took off when the FDA approved Novo Nordisk A/S’s (NYSE:NVO) Wegvoy (semaglutide) in 2021. Eli Lilly And Co’s (NYSE:LLY) Zepbound (tirzepatide) appears to spur the momentum after receiving FDA approval in November 2023. According to the FDA, limited supplies of Eli Lilly’s d

Related Keywords

North Carolina ,United States ,America ,Novo Nordisk ,Eli Lilly ,Ciara Kimsey ,Christine Romans ,Eli Lilly Mounjaro ,Edgardo Hernandez ,Rhonda Pacheco ,Us Lilly Diabetes Obesity Group Vice ,Eli Lilly And Co ,Obesity Group Vice President ,Stock Market Game ,Benzinga Pro ,Day Trial ,Patients Find Weight Loss Drug Zepbound ,Game Changer ,Makers See Production Delay Until ,